PeraMobile and PeraWatch vs VIDAvision
AI Verdict
Choose PeraMobile and PeraWatch if…
Choose PeraMobile and PeraWatch if your primary goal is real-time, system-wide surveillance of patient acuity to proactively identify and intervene with patients at risk of deterioration. This solution is ideal for organizations seeking to enhance patient safety through continuous monitoring, mobile alerts, and predictive analytics across their entire patient population.
View PeraMobile and PeraWatch →Choose VIDAvision if…
Choose VIDAvision if you require advanced, AI-powered quantitative analysis of chest CT scans for precise diagnosis, monitoring, and treatment planning of lung diseases. This tool is best suited for clinicians needing detailed insights into lung structure and function, including automated segmentation and 3D reconstruction, to inform complex respiratory care decisions.
View VIDAvision →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | PeraMobile and PeraWatch | VIDAvision |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | Software-only, integrated with EHRs, web-based access, mobile application, on user-provided hardware. | Cloud-based (VIDA Intelligence Platform) |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
PeraMobile and PeraWatchTool A, PeraMobile and PeraWatch, emphasizes mobile access for on-the-go clinicians and visual dashboards for patient condition trends, suggesting a design focused on broad clinical accessibility and quick interpretation. Tool B, VIDAvision, while powerful for imaging, involves specialized quantitative CT analysis and 3D reconstruction, which typically caters to a more specialized user base and may have a steeper learning curve for full utilization.
Clinical Value
PeraMobile and PeraWatchTool A provides system-wide predictive analytics for patient deterioration, enabling early intervention across various conditions and potentially reducing overall hospital costs and improving patient safety across a broad patient population. Tool B offers highly detailed quantitative analysis of chest CTs for specific lung diseases, leading to more precise diagnosis, monitoring, and treatment planning in a specialized domain. While both are FDA-cleared and offer significant value, Tool A's impact is broader across general patient care.
Pricing & Value
TieBoth tools require direct contact for pricing, and neither provides publicly disclosed details or specific ROI metrics. Without transparent pricing or comparative value studies, it is impossible to determine which offers better financial value or a more compelling return on investment.
Enterprise Readiness
PeraMobile and PeraWatchTool A explicitly mentions integration with major EHR vendors, web-based access, mobile applications, and deployment on user-provided hardware, demonstrating strong flexibility and integration capabilities for large healthcare systems. Tool B is cloud-based and HIPAA compliant, which is also enterprise-ready, but Tool A's description provides more explicit details about its adaptability within existing hospital IT infrastructure and workflows.
Innovation
VIDAvisionTool B leverages advanced AI and deep learning for automated lung and lobe segmentation, generating 'AI-powered digital biomarkers' and 3D reconstructions from CT scans, representing cutting-edge advancements in quantitative imaging analysis. Tool A's predictive analytics, while valuable and using the validated Rothman Index, are built upon more established methodologies in clinical decision support.
Support & Docs
TieNeither the provided structured facts nor general web searches offer specific details regarding the quality, availability, or scope of support and documentation for either product. Therefore, a meaningful comparison on this dimension is not possible, leading to a tie.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | PeraMobile and PeraWatch | VIDAvision |
|---|---|---|
| Tool Name | PeraMobile and PeraWatch | VIDAvision |
| Company | PeraHealth (acquired by Spacelabs Healthcare) | VIDA Diagnostics |
| Primary Function | Predictive analytics solutions to help healthcare providers identify at-risk patients sooner for earlier intervention, improve quality, and reduce costs, powered by the FDA-cleared Rothman Index. | FDA-cleared, AI-powered imaging software that provides comprehensive quantitative analysis of chest CT scans for the diagnosis, monitoring, and treatment planning of various lung diseases. |
| Key Technology/Methodology | FDA-cleared Rothman Index for real-time patient acuity scoring and predictive analytics. | AI-powered digital biomarkers, automated deep learning-based lung and lobe segmentation, Quantitative CT (QCT) analysis. |
| Specific Clinical Focus | Real-time patient acuity scoring and predictive analytics for patient deterioration. | Quantitative analysis of chest CT scans for various lung diseases. |
Videos
Demos, reviews, and walkthroughs featuring PeraMobile and PeraWatch and VIDAvision.